The Catheter-Related Bloodstream Infections Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medical development.
The Catheter-Related Bloodstream Infections market research report provides current treatment practices, Catheter-Related Bloodstream Infections emerging drugs, and Catheter-Related Bloodstream Infections market share of the individual therapies, current and forecasted 7MM Catheter-Related Bloodstream Infections market size. The Catheter-Related Bloodstream Infections market report also covers current Catheter-Related Bloodstream Infections treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key takeaways from the Catheter-Related Bloodstream Infections Market Research Report
- The growth of market size for Catheter-Related Bloodstream Infections is attributed to currently prescribed treatment regimens as well as emerging therapies. The market size for CRBSI was found to be USD 381.5 million in 2017.
- As per DelveInsight’s analysis, the total incident population of catheter-related bloodstream infection in the global market was found to be 4,114,882 in 2017. The estimates show a higher incidence of catheter-related bloodstream infection in India with 1,722,280 cases in 2017.
- The leading Catheter-Related Bloodstream Infections Companies are working such as CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and others.
- Promising Catheter-Related Bloodstream Infections Pipeline therapies such as TauroSept®, Bionecteur, BioFlo DuraMax Chronic Hemodialysis Catheter, Neutrolin, Heparin, MBI 226, NexSite HD Patients, Daptomycin, and others.
Discover more about therapies set to grab major Catheter-Related Bloodstream Infections market research report @ Catheter-Related Bloodstream Infections Market Size
Catheter-Related Bloodstream Infections Overview
Catheter-related bloodstream infection also known as catheter-related sepsis, defined as the presence of bacteremia originating from a catheter insertion. Antibiotics such as antibacterial and antifungal are used for the treatment of the disease. Antibiotic lock therapy is considered as adjunctive therapy in the treatment of CRBSI when catheter removal is not a favorable option. The current treatment options are used as off-label therapies and only a few non-antibiotic lock solutions are approved in Europe.
Catheter-Related Bloodstream Infections Epidemiology Insights in the 7MM
- Total Catheter-related bloodstream infection Incident Population
- Total Catheter-related bloodstream infection Diagnosed Incident Population
- Catheter-related bloodstream infection Diagnosed Incidence by Causative Pathogens scenario
To know more about leading the market growth in the Catheter-related bloodstream infection market, get a snapshot of the Catheter-related bloodstream infection Market Outlook
Catheter-Related Bloodstream Infections Treatment Market
The catheter-related bloodstream infection diagnosis remains a major challenge. Fever and chills that are often associated with catheter-related bloodstream infections are not specific. Furthermore, local catheter inflammation and phlebitis could exist in the absence of catheter-related bloodstream infection or even a local infection, as has been reported with peripherally inserted central catheters.
The ‘gold standard’ for the diagnosis of catheter-related bloodstream infection is the combination of positive blood culture with the same organism isolated from the catheter. However, a major diagnostic problem is that traditional methods of catheter culture necessitate the removal of the central venous catheters (CVC), whereby the line tip is either rolled on an agar plate or placed in a nutrient broth. It covers the details of conventional and current medical therapies available in the catheter-related bloodstream infection market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the United States and Spain.
Catheter-Related Bloodstream Infection Marketed Drugs
Neutrolin: CorMedix
Neutrolin (CRMD003), is a non-antibiotic, anti-infective developed by CorMedix as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping CVCs operating safely and efficiently. It is a catheter lock solution for the prevention of catheter-related bloodstream infection and maintenance of catheter patency in hemodialysis patients.
Taurosept: Geistlich Pharma
TauroSept is an antimicrobial solution (lock solution) developed by Geistlich Pharma for the prevention of catheter-related infection and is intended for installation in intravenous catheters between treatments to lock the catheter. It mainly contains antibacterial chemotherapeutic agent taurolidine.
Catheter-Related Bloodstream Infection Emerging Drugs
Mino-Lok: Citius Pharmaceuticals
Mino-Lok is an antibiotic lock solution used to treat patients with central line-associated bloodstream infection/catheter-related bloodstream infection. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Learn more about the emerging therapies & companies of the Catheter-Related Bloodstream Infection @ Catheter-Related Bloodstream Infection Market Outlook
Scope of the Catheter-Related Bloodstream Infection Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Forecast Period- 2022-2032
- Catheter-Related Bloodstream Infections Companies- CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and others.
- Catheter-Related Bloodstream Infections Pipeline therapies- TauroSept®, Bionecteur, BioFlo DuraMax Chronic Hemodialysis Catheter, Neutrolin, Heparin, MBI 226, NexSite HD Patients, Daptomycin, and others
- Catheter-Related Bloodstream Infections Pipeline Therapeutic Assessment: Catheter-Related Bloodstream Infections Current marketed and emerging therapies
- Catheter-Related Bloodstream Infections Market Dynamics: Catheter-Related Bloodstream Infections Market Drivers and Barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Catheter-Related Bloodstream Infections Market Access and Reimbursement
Table of Content
1. Key Insights
2. Catheter-Related Bloodstream Infection Executive Summary
3. Competitive Intelligence Analysis for Catheter-Related Bloodstream Infection (CRBSI)
4. Catheter-Related Bloodstream Infection (CRBSI): Market Overview at a Glance
5. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview
6. Patient Journey
7. Catheter-Related Bloodstream Infection (CRBSI) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Catheter-Related Bloodstream Infection (CRBSI) Unmet Needs
10. Key Endpoints of Catheter-Related Bloodstream Infection (CRBSI) Treatment
11. Catheter-Related Bloodstream Infection (CRBSI) Marketed Products
12. Catheter-Related Bloodstream Infection (CRBSI) Emerging Therapies
13. Catheter-Related Bloodstream Infection (CRBSI): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Catheter-Related Bloodstream Infection Market Outlook
16. Access and Reimbursement Overview of Catheter-Related Bloodstream Infection (CRBSI)
17. KOL Views
18. Catheter-Related Bloodstream Infection Market Drivers
19. Catheter-Related Bloodstream Infection Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Got Queries? Consult with our Business Expert @ Catheter-Related Bloodstream Infection Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/